Compare ARK Genomic Revolution ETF (ARKG) vs Baker Hughes Co (BKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Baker Hughes Co — how do they compare? ARK Genomic Revolution ETF trades at $41.28, while Baker Hughes Co trades at $58.11 (market cap $57.10B). The key difference: Baker Hughes Co pays a 1.6% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Baker Hughes Co nearer its low. Which is the better fit depends on your goals.
| ARKG | BKR | |
|---|---|---|
Sector | Sector/Thematic | Energy |
52-Week High | $43.57 | $69.67 |
52-Week Low | $23.09 | $38.68 |
Market Cap | — | $57.10B |
Enterprise Value | — | $58.50B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Baker Hughes (BKR) trades at $57.56, up 0.63% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with P/E of 18.39, ROE of 17.14%, and consistent revenue growth from $21.2B in 2022 to $27.7B in 2025. Recent contract wins with Cheniere and Kodiak Gas Services highlight expansion in LNG and power infrastructure, supporting long-term growth prospects.
BKR presents a compelling investment case with analyst consensus price target of $73.45 (27% upside) and 66.7% buy ratings. Key opportunities include LNG infrastructure expansion and energy transition projects, while risks involve oil price volatility and execution of the $13.6B Chart Industries acquisition. The stock's current valuation appears reasonable given earnings growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →
